Skip to main content

Advertisement

Table 3 Univariate analyses of survival outcomes by patient and treatment-related factors

From: Outcomes of patients with loco-regionally recurrent or new primary squamous cell carcinomas of the head and neck treated with curative intent reirradiation at Mayo Clinic

  Overall Survival, HR (95 % CI) Time to loco-regional recurrence, mos (95 % CI) Time to distant metastases, mos (95 % CI)
LRR vs. NP SCCHN 0.84 (0.49–1.49) 1.05 (0.51–2.38) 0.99 (0.58–1.77)
P = 0.53 P = 0.91 P = 0.96
Age at diagnosis of LRR/NP SCCHN 1.4 (0.84–2.36) 1.01 (0.52–2.03) 1.62 (0.97–2.77)
  < 60 vs. ≥ 60 P = 0.2 P = 0.97 P = 0.07
Sex 0.92 (0.52–1.71) 0.53 (0.27–1.15) 0.98 (0.54–1.91)
 Male vs. Female P = 0.78 P = 0.1 P = 0.95
Tobacco abuse 0.67 (0.86–2.72) 1.84 (0.26–1.12) 0.82 (0.71–2.16)
  < 20 PY vs. > 20 PY P = 0.16 P = 0.1 P = 0.48
Post-operative vs. Definitive RRT 0.67 (0.4–1.11) 0.62 (0.31–1.23) 0.67 (0.4–1.1)
P = 0.12 P = 0.17 P = 0.12
Time since primary SCCHN 0.77 (0.44–1.3) 1.19 (0.43–1.73) 0.79 (0.75–2.18)
  < 24 mos vs. ≥ 24 mos P = 0.33 P = 0.63 P = 0.39
Chemotherapy vs. no chemotherapy with RRT 1.47 (0.82–2.84) 2.43 (1.02–7.16) 1.12 (0.66–1.98)
P = 0.2 P = 0.04 P = 0.68
Platinum vs. cetuximab with RRT 0.65 (0.36–1.22) 0.4 (0.19–0.86) 0.65 (0.33–1.31)
P = 0.18 P = 0.02 P = 0.22
IMRT versus other 0.99 (0.4–3.32) 2.03 (0.43–36.2) 1.21 (0.49–4.04)
P = 0.99 P = 0.44 P = 0.71
  1. CI confidence interval, HR hazard ratio, IMRT intensity modulated radiation therapy, LRR loco-regionally recurrent, NP new primary, NR not reached, PY pack-years, RRT reirradiation therapy, SCCHN squamous cell carcinoma of head and neck